{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:47:44Z","timestamp":1788558464464,"version":"build-2803163510"},"reference-count":41,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,3,24]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cold agglutinin disease (CAD) causes predominantly extravascular hemolysis and anemia via complement activation. Sutimlimab is a novel humanized monoclonal antibody directed against classical pathway complement factor C1s. We aimed to evaluate the safety and efficacy of long-term maintenance treatment with sutimlimab in patients with CAD. Seven CAD patients treated with sutimlimab as part of a phase 1B study were transitioned to a named patient program. After a loading dose, patients received biweekly (once every 2 weeks) infusions of sutimlimab at various doses. When a patient\u2019s laboratory data showed signs of breakthrough hemolysis, the dose of sutimlimab was increased. Three patients started with a dose of 45 mg\/kg, another 3 with 60 mg\/kg, and 1 with a fixed dose of 5.5 g every other week. All CAD patients responded to re-treatment, and sutimlimab increased hemoglobin from a median initial level of 7.7 g\/dL to a median peak of 12.5 g\/dL (P = .016). Patients maintained near normal hemoglobin levels except for a few breakthrough events that were related to underdosing and which resolved after the appropriate dose increase. Four of the patients included were eventually treated with a biweekly 5.5 g fixed-dose regimen of sutimlimab. None of them had any breakthrough hemolysis. All patients remained transfusion free while receiving sutimlimab. There were no treatment-related serious adverse events. Overlapping treatment with erythropoietin, rituximab, or ibrutinib in individual patients was safe and did not cause untoward drug interactions. Long-term maintenance treatment with sutimlimab was safe, effectively inhibited hemolysis, and significantly increased hemoglobin levels in re-exposed, previously transfusion-dependent CAD patients.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001321","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T15:39:58Z","timestamp":1584373198000},"page":"997-1005","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":32,"title":["Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0995-7178","authenticated-orcid":false,"given":"Georg","family":"Gelbenegger","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2286-1077","authenticated-orcid":false,"given":"Christian","family":"Schoergenhofer","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Derhaschnig","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Buchtele","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sillaber","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fillitz","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hanusch Krankenhaus, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Schenk","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Universit\u00e4tsklinikum St. P\u00f6lten, St. P\u00f6lten, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"D\u2019Sa","sequence":"first","affiliation":[{"name":"University College London Hospitals (UCLH) Centre for Waldenstr\u00f6ms Macroglobulinaemia and Related Conditions, UCLH, National Health Service (NHS) Foundation Trust, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronwyn","family":"Cartwright","sequence":"first","affiliation":[{"name":"Worthing Hospital, Western Sussex Hospitals, NHS Foundation Trust, Worthing, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Gilbert","sequence":"first","affiliation":[{"name":"Band Therapeutics, LLC, Lexington, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5652-7977","authenticated-orcid":false,"given":"Bernd","family":"Jilma","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9826-1062","authenticated-orcid":false,"given":"Ulrich","family":"Jaeger","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,3,16]]},"reference":[{"issue":"10","key":"2020032411302882100_B1","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJM197709082971005","article-title":"Biologic activity of cold-reacting autoantibodies (first of two parts)","volume":"297","author":"Pruzanski","year":"1977","journal-title":"N Engl J Med"},{"issue":"4","key":"2020032411302882100_B2","first-page":"460","article-title":"Primary chronic cold agglutinin disease: a population based clinical study of 86 patients","volume":"91","author":"Berentsen","year":"2006","journal-title":"Haematologica"},{"issue":"7","key":"2020032411302882100_B3","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood-2013-02-474437","article-title":"Cold agglutinin disease","volume":"122","author":"Swiecicki","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2020032411302882100_B4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3324\/haematol.2013.091702","article-title":"Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma","volume":"99","author":"Randen","year":"2014","journal-title":"Haematologica"},{"issue":"11","key":"2020032411302882100_B5","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2010-03-259325","article-title":"How I treat autoimmune hemolytic anemias in adults","volume":"116","author":"Lechner","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2020032411302882100_B6","first-page":"439","article-title":"Cold agglutinin disease","volume":"91","author":"Gertz","year":"2006","journal-title":"Haematologica"},{"issue":"4","key":"2020032411302882100_B7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1600-0609.1999.tb01887.x","article-title":"Clinical immunology of chronic cold agglutinin disease","volume":"63","author":"Ulvestad","year":"1999","journal-title":"Eur J Haematol"},{"issue":"3","key":"2020032411302882100_B8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood.V56.3.409.409","article-title":"The variability of hemolysis in the cold agglutinin syndrome","volume":"56","author":"Rosse","year":"1980","journal-title":"Blood"},{"issue":"4","key":"2020032411302882100_B9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.blre.2017.02.003","article-title":"Complementopathies","volume":"31","author":"Baines","year":"2017","journal-title":"Blood Rev"},{"issue":"8","key":"2020032411302882100_B10","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.4049\/jimmunol.1403068","article-title":"Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth","volume":"194","author":"Coulthard","year":"2015","journal-title":"J Immunol"},{"key":"2020032411302882100_B11","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement System Part I - Molecular Mechanisms of Activation and Regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"issue":"22","key":"2020032411302882100_B12","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1182\/blood-2015-06-640995","article-title":"Complement in hemolytic anemia","volume":"126","author":"Brodsky","year":"2015","journal-title":"Blood"},{"key":"2020032411302882100_B13","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/asheducation-2016.1.226","article-title":"Cold agglutinin disease","volume":"2016","author":"Berentsen","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"2020032411302882100_B14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000438964","article-title":"Role of complement in autoimmune hemolytic anemia","volume":"42","author":"Berentsen","year":"2015","journal-title":"Transfus Med Hemother"},{"issue":"4","key":"2020032411302882100_B15","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1172\/JCI108547","article-title":"The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man","volume":"58","author":"Jaffe","year":"1976","journal-title":"J Clin Invest"},{"issue":"26","key":"2020032411302882100_B16","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1182\/blood-2014-02-556027","article-title":"TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins","volume":"123","author":"Shi","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2020032411302882100_B17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.autrev.2006.09.008","article-title":"The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias","volume":"6","author":"Ruiz-Arg\u00fcelles","year":"2007","journal-title":"Autoimmun Rev"},{"issue":"19","key":"2020032411302882100_B18","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/bloodadvances.2018024190","article-title":"Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial","volume":"2","author":"R\u00f6th","year":"2018","journal-title":"Blood Adv"},{"key":"2020032411302882100_B19","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting [published online ahead of print 5 December 2019]","author":"J\u00e4ger","journal-title":"Blood Rev"},{"issue":"8","key":"2020032411302882100_B20","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2003-10-3597","article-title":"Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients","volume":"103","author":"Berentsen","year":"2004","journal-title":"Blood"},{"issue":"17","key":"2020032411302882100_B21","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1182\/blood-2010-06-288647","article-title":"High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease","volume":"116","author":"Berentsen","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2020032411302882100_B22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2017-04-778175","article-title":"Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial","volume":"130","author":"Berentsen","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2020032411302882100_B23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/bjh.15109","article-title":"How I manage patients with cold agglutinin disease","volume":"181","author":"Berentsen","year":"2018","journal-title":"Br J Haematol"},{"issue":"4","key":"2020032411302882100_B24","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/cpt.1111","article-title":"A randomized, first-in-human, healthy volunteer trial of sutimlimab, a humanized antibody for the specific inhibition of the classical complement pathway","volume":"104","author":"Bartko","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"2020032411302882100_B25","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2018-06-856930","article-title":"Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial","volume":"133","author":"J\u00e4ger","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2020032411302882100_B26","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/j.jid.2019.04.025","article-title":"Specific inhibition of the classical complement pathway prevents C3 deposition along the dermal-epidermal junction in bullous pemphigoid","volume":"139","author":"Freire","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"4","key":"2020032411302882100_B27","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/ajt.14528","article-title":"Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial","volume":"18","author":"Eskandary","year":"2018","journal-title":"Am J Transplant"},{"issue":"37","key":"2020032411302882100_B28","doi-asserted-by":"crossref","DOI":"10.3791\/1923","article-title":"Measuring the 50% haemolytic complement (CH50) activity of serum","author":"Costabile","year":"2010","journal-title":"J Vis Exp"},{"key":"2020032411302882100_B29","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.928.928","article-title":"Incidence of thromboembolic events is increased in a retrospective analysis of a large cold agglutinin disease (CAD) cohort [abstract]","volume":"130","author":"Broome","year":"2017","journal-title":"Blood"},{"key":"2020032411302882100_B30","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0049-3848(16)30365-6","article-title":"Examining coagulation-complement crosstalk: complement activation and thrombosis","volume":"141","author":"Foley","year":"2016","journal-title":"Thromb Res"},{"issue":"1-2","key":"2020032411302882100_B31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-3083.2001.00960.x","article-title":"Acute phase haemolysis in chronic cold agglutinin disease","volume":"54","author":"Ulvestad","year":"2001","journal-title":"Scand J Immunol"},{"issue":"3","key":"2020032411302882100_B32","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood.V69.3.820.820","article-title":"Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases","volume":"69","author":"Liesveld","year":"1987","journal-title":"Blood"},{"key":"2020032411302882100_B33","unstructured":"Fattizzo B , LanguilleL, LevatiG, et al Evidence based use of erythropoietin in patients with autoimmune hemolytic anemia: a multicenter international study [abstract]. Presented at the 24th European Hematology Association Congress; 13-16 June 2019; Amsterdam, The Netherlands. Abstract S900. Available at: https:\/\/library.ehaweb.org\/eha\/2019\/24th\/267483\/bruno.fattizzo.evidence.based.use.of.erytrhopoietin.in.patients.with.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D1550%2Aot_id%3D20974%2Afeatured%3D16435. Accessed 1 September 2019."},{"issue":"3","key":"2020032411302882100_B34","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1172\/JCI90962","article-title":"The role of the complement system in cancer","volume":"127","author":"Afshar-Kharghan","year":"2017","journal-title":"J Clin Invest"},{"issue":"5","key":"2020032411302882100_B35","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/ki.1991.102","article-title":"Diagnostic significance of hypocomplementemia","volume":"39","author":"Hebert","year":"1991","journal-title":"Kidney Int"},{"issue":"6","key":"2020032411302882100_B36","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ccr3.881","article-title":"Ibrutinib-induced severe liver injury","volume":"5","author":"Nandikolla","year":"2017","journal-title":"Clin Case Rep"},{"issue":"7","key":"2020032411302882100_B37","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40264-013-0048-4","article-title":"Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf"},{"issue":"11","key":"2020032411302882100_B38","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.3109\/10428194.2016.1154955","article-title":"Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion","volume":"57","author":"Cavazzini","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2020032411302882100_B39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000456002","article-title":"Ibrutinib is effective in the treatment of autoimmune haemolytic anaemia in mantle cell lymphoma","volume":"10","author":"Galinier","year":"2017","journal-title":"Case Rep Oncol"},{"issue":"5","key":"2020032411302882100_B40","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/bjh.13328","article-title":"Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia","volume":"170","author":"Manda","year":"2015","journal-title":"Br J Haematol"},{"issue":"12","key":"2020032411302882100_B41","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/bloodadvances.2019000036","article-title":"Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment","volume":"3","author":"Hill","year":"2019","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/6\/997\/1720024\/advancesadv2019001321.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/6\/997\/1720024\/advancesadv2019001321.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T22:20:25Z","timestamp":1666131625000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/6\/997\/452695\/Inhibition-of-complement-C1s-in-patients-with-cold"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,16]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,3,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001321","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,16]]}}}